Received for publication August 31, 2004.
Revised October 18, 2004.
Accepted for publication October 18, 2004.

Valdecoxib: Assessment of COX-2 potency and selectivity

Abstract

The discovery of a second isoform of cyclooxygenase (COX) led to the search for compounds that could selectively inhibit COX-2 in humans, while sparing prostaglandin formation from COX-1. Celecoxib and rofecoxib were among the molecules developed from these efforts. We report here the pharmacological properties of a third selective COX-2 inhibitor, valdecoxib, which is the most potent and in vitro selective of the marketed COX-2 inhibitors that we have studied. Recombinant human COX-1 and COX-2 were used to screen for new highly potent and in vitro selective COX-2 inhibitors and compare kinetic mechanisms of binding and enzyme inhibition with other COX inhibitors. Valdecoxib potently inhibits recombinant COX-2, with an IC₅₀ of 0.005 µM; this compares with IC₅₀ values of 0.05 µM for celecoxib, 0.5 µM for rofecoxib and 2.1 µM for etoricoxib. Unique binding interactions of valdecoxib with COX-2 translate into a fast rate of inactivation of COX-2 110,000 M-1 sec-1 (compared to 7,000 M-1 sec-1 for rofecoxib and 80 M-1 sec-1 for etoricoxib). The overall saturation binding affinity for COX-2 of valdecoxib is 2.6 nM (compared to 1.6 nM for celecoxib, 51 nM for rofecoxib and 260 nM for etoricoxib), with a slow off rate (t1/2 ~ 98 min). Valdecoxib inhibits COX-1 in a competitive fashion only at very high concentrations (IC₅₀ = 150 uM). Collectively, these data provide a mechanistic basis for the potency and in vitro selectivity of valdecoxib for COX-2. Valdecoxib showed similar activity in the human whole blood COX assay (COX-2 IC₅₀ = 0.24 uM; COX-1 IC₅₀ = 21.9 uM). We also determined whether this in vitro potency and selectivity translated to significant potency in vivo. In rats valdecoxib demonstrated marked potency in acute and chronic models of inflammation (air pouch ED₅₀ = 0.06 mg/kg; paw edema ED₅₀ = 5.9 mg/kg; adjuvant arthritis ED₅₀ = 0.03 mg/kg). In these same animals, COX-1 was spared at doses greater than 200 mg/kg. These data provide a basis for the observed potent anti-inflammatory activity of valdecoxib in humans.

Key words: COX-2, PGH2, Prostaglandin, Synthase, inhibitor, valdecoxib

This article has been cited by other articles:

				A. M. Simon and J. P. O'Connor Dose and Time-Dependent Effects of Cyclooxygenase-2 Inhibition on Fracture-Healing J. Bone Joint Surg. Am., March 1, 2007; 89(3): 500 - 511. [Abstract] [Full Text] [PDF]

				C. Brenneis, T. J. Maier, R. Schmidt, A. Hofacker, L. Zulauf, P.-J. Jakobsson, K. Scholich, and G. Geisslinger Inhibition of prostaglandin E2 synthesis by SC-560 is independent of cyclooxygenase 1 inhibition FASEB J, July 1, 2006; 20(9): 1352 - 1360. [Abstract] [Full Text] [PDF]

				E. Fosslien Cardiovascular Complications of Non-Steroidal Anti-Inflammatory Drugs Ann. Clin. Lab. Sci., October 1, 2005; 35(4): 347 - 385. [Abstract] [Full Text] [PDF]